（1）通过肿瘤基因组等多组学手段解析了胰腺神经内分泌瘤（PanNETs）、肝癌、食管癌等消化道肿瘤的关键分子改变及其空间异质性，发现ATRX、DAXX、TERT、BAI1、KLF4等新驱动基因和驱动突变，从中发现多个具有临床价值的标志物和分子分型。最先发现的ATRX等3个基因或突变被WHO消化系统肿瘤分类、WHO中枢神经系统肿瘤分类等权威指南推荐为PanNETs、胶质瘤的诊断标志物，并进入病理科临床检测。（Science. 2011a, PNAS.2013, Gastroenterology. 2017, Clin Cancer Res. 2018, GUT 2021, Cancer Cell. accepted）

（2）揭示了PanNETs中ATRX突变维护肿瘤细胞端粒和MEN1突变激活肿瘤代谢重编程的致癌机制。通过功能基因组筛选，发现了可靶向ATRX和MEN1突变的新治疗靶点，揭示其协同致死作用的分子机制，成功筛选获得了特异性靶向治疗药物，并在临床试验中证明了抗风湿药来氟米特治疗MEN1突变肿瘤的安全性和有效性，为放、化疗均不敏感的PanNETs等肿瘤提供了潜在的有效治疗及预防方案（Science. 2011b；Cancer Res.2020；Cell Res.2022）。

1.   Wang P, Song Q, Ren J, Zhang W, Wang Y, Zhou L, WangD, Chen K, Jiang L, Zhang B, Chen W, Qu C*, Zhao H*, JiaoY*. Simultaneous analysis of mutations andmethylations in circulating cell-free DNA for hepatocellular carcinomadetection. Sci Transl Med. 2022 Nov 23;14(672).

2.   Ma Y, Zhu Q, Wang X, Liu M, Chen Q, Jiang L, Chi Y,Zeng YX*, Zhao H*, Jiao Y*. Synthetic lethal screeningidentifies DHODH as a target for MEN1-mutated tumor cells. Cell Res. 2022 Jun;32(6):596-599

3.   He S, Zeng F, Yin H, Wang P, Bai Y, Song Q, Chu J,Huang Z, Liu Y, Liu H, Chen Q, Liu L, Zhou J, Hu H, Li X, Li T, Wang G*, Cai J*,Jiao Y*, Zhao H*. Moleculardiagnosis of pancreatobiliary tract cancer by detecting mutations andmethylation changes in bile samples. EClinicalMedicine. 2022 Nov17;55:101736

4.   Zhao L, Jiang L, Liu Y, Wang X, Song J, Sun Y, BaiY, Dong X, Sun L*, Wu J*, Jiao Y*, Zhao X*. Integratedanalysis of circulating tumour cells and circulating tumour DNA to detectminimal residual disease in hepatocellular carcinoma. ClinTransl Med. 2022 Apr;12(4):e793.

5.   Liu W, Li Y, Tang Y, Song Q, Wang J, Li N, Chen S,Shi J, Wang S, Li Y, Jiao Y*, Zeng Y*, Jin J*. Responseprediction and risk stratification of patients with rectal cancer afterneoadjuvant therapy through an analysis of circulating tumour DNA. EBioMedicine.2022 Apr;78:103945

6.   Zhao D, Yue P, Wang T, Wang P, Song Q, Wang J, JiaoY*. Personalized analysis of minimal residual cancer cells inperitoneal lavage fluid predicts peritoneal dissemination of gastric cancer. J Hematol Oncol. 2021;14(1):164.

7.   Fujikura K, Hosoda W, Felsenstein M, Song Q, etal. Jiao Y*, Wood LD*. Multiregionwhole-exome sequencing of intraductal papillary mucinous neoplasms revealsfrequent somatic KLF4 mutations predominantly in low-grade regions. Gut. 2021May;70(5):928-939

8.   Zhu Q, Ma Y, Liang J, Wei Z, Li M, Zhang Y, Liu M,He H, Qu C, Cai J, Wang X*, Zeng Y*, Jiao Y*. AHR mediates theaflatoxin B1 toxicity associated with hepatocellular carcinoma. Signal Transduct Target Ther. 2021Aug 9;6(1):299.

9.   Ma Y, Zhu Q, Liang J, Li Y, Li M, Zhang Y, Wang X*, Zeng Y*, JiaoY*.A CRISPR knockout negative screen reveals synergy between CDKs inhibitor andmetformin in the treatment of human cancer in vitro and in vivo. Signal Transduct Target Ther. 2020 Aug 19;5(1):152

10.Liang J, Zhao H, Diplas BH, Liu S, Liu J, Wang D, LuY, Zhu Q, Wu J, Wang W, Yan H, Zeng YX, Wang X*, JiaoY*.Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-MutantCancers to WEE1 Inhibition. Cancer Res. 2020 Feb 1;80(3):510-523

11.Qu C*, Wang Y, Wang P, Chen K, Wang M, ZengH, et al. Zeng YX, Cavenee WK*, JiaoY*. Detection of early-stage hepatocellular carcinoma in asymptomaticHBsAg-seropositive individuals by liquid biopsy. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6308-6312.

12. Xu M, Zhang WL, Zhu Q, Zhang S, Yao YY,Xiang T, Feng QS, Zhang Z, Peng RJ, Jia WH, He GP, Feng L, Zeng ZL, Luo B, XuRH, Zeng MS, Zhao WL, Chen SJ, Zeng YX*,Jiao Y*. Genome-wideprofiling of Epstein-Barr virus integration by targeted sequencing inEpstein-Barr virus associated malignancies. Theranostics.2019 Jan 30;9(4):1115-1124

13.Wu RC,Wang P, Lin SF, Zhang M, Song Q, Chu T, Wang BG, Kurman RJ, Vang R, Kinzler K,Tomasetti C*, Jiao Y*, Shih IM*,Wang TL*. Genomic landscape andevolutionary trajectories of ovarian cancer precursor lesions. J Pathol. 2019 May;248(1):41-50.

14. Diplas BH, He X, Brosnan-Cashman JA, Liu H,Chen LH, Wang Z, Moure CJ, Killela PJ, Loriaux DB, Lipp ES, Greer PK, Yang R,Rizzo AJ, Rodriguez FJ, Friedman AH, Friedman HS, Wang S, He Y, McLendon RE,Bigner DD, Jiao Y*, WaitkusMS*, Meeker AK*, Yan H*. The genomic landscape of TERT promoter wildtype-IDHwildtype glioblastoma. Nat Commun. 2018 May 25;9(1):2087.

15.HuangJ*, Xu B*, Mo H, Zhang W, Chen X, Wu D, Qu D, Wang X, Lan B, Yang B, Wang P,Zhang H, Yang Q, Jiao Y*.Safety, activity and biomarkers of SHR-1210, an anti-PD-1 antibody, forpatients with advanced esophageal carcinoma. Clin Cancer Res. 2018 Mar15;24(6):1296-1304.

16.ZhangW, He H, Zang M, Wu Q, Zhao H, Lu L-l, Ma P, Zheng H, Wang N, Zhang Y, He S,Chen X, Wu Z, Wang X, Cai J, Liu Z, Sun Z, Zeng Y-X*, Qu C*, Jiao Y*. Genetic Features ofAflatoxin-associated Hepatocellular Carcinomas. Gastroenterology. 2017Jul;153(1):249-262.

17.ShanL, Jiang P, Xu F, Zhang W, Guo L, Wu J, Zeng Y, Jiao Y*, Ying J*. BIRC6-ALK, a Novel Fusion Gene in ALKBreak-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib. J Thorac Oncol. 2015 Jun;10(6):e37-9.

18.HuangDS, Wang Z, He XJ, Diplas BH, Yang R, Killela PJ, Meng Q, Ye ZY, Wang W, JiangXT, Xu L, He XL, Zhao ZS, Xu WJ, Wang HJ, Ma YY, Xia YJ, Li L, Zhang RX, Jin T,Zhao ZK, Xu J, Yu S, Wu F, Liang J, Wang S, Jiao Y*, Yan H*, Tao HQ*. Recurrent TERT promoter mutationsidentified in a large-scale study of multiple tumour types are associated withincreased TERT expression and telomerase activation. Eur J Cancer. 2015May;51(8):969-76.

19.Killelaa PJ#, Reitmana ZJ#, JiaoY#, Bettegowda C#, et al., Papadopoulos N,Kinzler KW, Vogelstein B, Yan H. TERT promoter mutations occur frequently ingliomas and a subset of tumors derived from cells with low rates ofself-renewal. Proc Natl Acad Sci US A. 2013 Apr 9;110(15):6021-6

20.JiaoY#, Pawlik TM#, Anders RA#, et al. VogelsteinB, Kinzler KW, Papadopoulos N, and Wood LD. Exome sequencing reveals frequentinactivating mutations in chromatin remodeling genes in intrahepaticcholangiocarcinomas. Nat Genet.2013; Dec;45(12):1470-3

21.Heaphy CM#, de Wilde RF#, JiaoY#, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ,Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H,Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B,Hruban RH, Maitra A, Papadopoulos N, Meeker AK. Altered telomeres in tumors with ATRX and DAXX mutations.  Science.2011 Jul 22;333(6041):425.

22.JiaoY#, Shi C#, Edil BH, de Wilde RF, KlimstraDS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, DiazLA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1,and mTOR pathway genes are frequently altered in pancreatic neuroendocrinetumors. Science. 2011 Mar4;331(6021):1199-203.

香港求是基金会 求是杰出青年学者奖，2016

科技部中青年科技创新领军人才，2018

万人计划 科技创新领军人才，2019

中国青年科技奖，2019

国家杰出青年基金, 2023-2027

1.基于多种组学及生物信息学分析肿瘤分子改变时空异质性及肿瘤分子分型；

2.基于CRISPR-Cas9协同致死筛选的功能基因组研究，发现针对驱动基因突变的新靶点、新药物；

3.基于ctDNA多组学标志物的肿瘤液体活检技术在肿瘤早筛和疗效评估的应用。